BioSpace News Archive

Mateon Therapeutics Inc. report several peer-reviewed publications derived from its R&D effort against COVID-19..

Global health service company Cigna Corporation continues to lead a rapid response to the challenges presented by COVID-19 and reported strong first quarter 2020 results driven by focused execution across its businesses.

ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, has generated intrabodies highly selective for misfolded forms of TAR DNA-binding protein 43 implicated in amyotrophic lateral sclerosis, frontotemporal dementia and several other neurologic disorders.

GAAP earnings per share was $0.32; Operating EPS¹ was $0.59. Operating EPS excludes significant items in the quarter, totaling $0.27 per share, related to restructuring and asset related charges; early extinguishment of debt; and integration and separation costs.

GAAP revenue of $1,163.4 million for the three months ended March 31, 2020, representing growth of 4.0%, 3.8% on an adjusted basis, and 4.4% on a constant currency adjusted basis compared to the same period in 2019.

Reports Record First Quarter Consumer Self-Care Americas Net Sales

Bausch Health Companies Inc. and Salix Pharmaceuticals announced that fourteen new scientific posters featuring research and data spanning Salix’s GI portfolio – including rifaximin, plecanatide, methylnaltrexone bromide and PEG-3350, electrolytes and ascorbate for oral solution – will be accessible on Digestive Disease Week®'s ePosters and ePapers free, online portal beginning Saturday, May 2, 2020.

Reports revenue growth of 9% on a reported and organic basis driven by Companion Animal Group (“CAG”) Diagnostics recurring revenue growth of 10% reported and organic

Codexis, Inc., a leading protein engineering company, announces that it will report first quarter 2020 financial results after market close on Thursday, May 7, 2020.

Sunesis Pharmaceuticals, Inc. announced that it will host a conference call on Thursday, May 7th, 2020 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the first quarter ended March 31, 2020.